Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Complete Response (CR) or Partial Response (PR)
Tumor response was defined as the number of participants whose best response was CR or PR, per the Response Evaluation Criteria in Solid Tumor (RECIST): CR: disappearance of all target/non-target lesions; PR: >= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD.
Baseline to end of study drug therapy (up to 65 weeks).
United States: Food and Drug Administration
|Mayo Clinic Jacksonville||Jacksonville, Florida 32224|
|Montefiore Medical Center||Bronx, New York 10467-2490|
|University Of Texas Md Anderson Cancer Ctr||Houston, Texas 77030|
|Dana-Farber Cancer Inst||Boston, Massachusetts 02115|
|Ucsf-Comprehensive Cancer Center||San Francisco, California 94115|